BB's Stock Haven

[jaybird249]

RNN $.83 +$.08 TWO bullish articles:

http://finance.yahoo.com/news/Rexahn-Pharmaceuticals-Amex-iw-3464506009.html?x=0&.v=1

http://finance.yahoo.com/news/Rexahn-Pharmaceuticals-Amex-iw-3464506009.html?x=0&.v=1

Most undervalued biotech firm! 9-Feb-10 10:40 pm I have been doing due diligence on this company since late last year. The company has three breakthrough products in phase 2. In fact two of them have successfully completed the phase 2a or proof of concept phase which makes those products very viable licensing targets for big pharma. These products, Serdaxin and Zoraxel, are the same active ingredient. Serdaxin is a novel and new method of treating depression without any major side effects. This is an $11 billion worldwide market yet it does not effectively treat two thirds of all depressed patients. Serdaxin since it works on both seratonin and dopamine is the only clinically evaluated drug that has successfully been able to increase both. This allows mild to moderate depression to be treated without any major relapses for the patients that are not just constantly negative but who have lost their positive state or have both attributes. In the next 4 years over $5 billion of that $11 billion will come off patent. This means that RNN is a prime candidate to replace those compounds and expand the market to solve patients needs who did not do well on prozac or zoloft. In addition it appears Serdaxin also is a neuroprotector. Thc company plans on starting phase 2 trials on parkinson within months. In animals it has shown the ability to keep neuronal cells from dying from Parkinsons or Alzheimers disease. This drug is safe and effective so it will be easy and fast to see if this is true. Depression is in 60% of all parkinson and alzheimer patients. More exciting is Zoraxel. It is a novel way to treat Erectile Dysfunction. It works on the Libido(desire) as well as erection and ejaculation. Viagra and its bretheren only work on blood flow not desire. This makes you want to have sex. About half the patients do not respond to Viagra. This drug works on all patient types. The phase 2a top line results were positive but in April you will see the real results and a new drug star will be born. This is the same active as serdaxin. This compound is a true wonder drug. It will capture the public's imagination when the final results will be reported. In addition this market is over $ 5 billion worldwide and Viagra is off patent in two years. Pfe and the others will need a new compound that works on many more patients in a more effective and pleasurable way. Zoraxel will be the subject of a bidding war among the big Pharma companies. These two drugs attack a combined $16 billion market that a large part is going generic and will need new more effective compounds. They have great phase 2a results and are very safe. Watch how the big pharma companies kill themselves to deal with RNN once they find out about them. This company has been below the radar screen. However they are opening up to the world and look out. Just to start this company should be a $300 million to $500 million market cap now. That implies a $4-$7/shr price right away.